Market Overview

UPDATE: Bank Of America Downgrades ConAgra Foods On Mixed Factors


In a report published Thursday, Bank of America analyst Bryan D. Spillane downgraded the rating on ConAgra Foods (NYSE: CAG) from Buy to Underperform, and lowered the price target from $34.00 to $30.00.

In the report, Bank of America noted, “We are downgrading ConAgra Foods (CAG) from Buy to Underperform. While we continue to believe that there is potential for the company to create an advantaged Private Brands business model by delivering higher quality products at a lower cost, it is clear given yesterday's announcement that it will take longer for the company to realize its full potential. Valuation is attractive but with muted earnings growth, relatively high debt levels and no dividend growth in the near term we expect the stock to underperform its peers over the next 12 months.”

ConAgra Foods closed on Wednesday at $30.47.

Latest Ratings for CAG

Sep 2019DowngradesBuyNeutral
Jun 2019MaintainsBuy
Jun 2019Initiates Coverage OnOutperform

View More Analyst Ratings for CAG
View the Latest Analyst Ratings

Posted-In: Bank of America Bryan D. SpillaneAnalyst Color Downgrades Analyst Ratings


Related Articles (CAG)

View Comments and Join the Discussion!

Latest Ratings

LOWRBC CapitalMaintains129.0
MARRBC CapitalMaintains148.0
CRLSunTrust Robinson HumphreyMaintains162.0
CFRSunTrust Robinson HumphreyMaintains105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: Bank Of America Reiterates On Envision Healthcare After Phoenix Deal Closes

UPDATE: MLV & Co. Initiates Coverage On Sorrento Therapeutics On Good Cynviloq Potential